TDMS Study 96002-02 Pathology Tables
NTP Experiment-Test: 96002-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 14DAY REPEATED DIAZOAMINOBENZENE (DAAB) Date: 09/27/00
Route: SKIN APPLICATION Time: 08:19:20
FINAL#1; 17 DAY REPEATED DOSE
Facility: BIORELIANCE
Chemical CAS #: 136-35-6
Lock Date: 01/21/99
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96002-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 14DAY REPEATED DIAZOAMINOBENZENE (DAAB) Date: 09/27/00
Route: SKIN APPLICATION Time: 08:19:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 12.5 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 5 5 5 5 5 5
Early Deaths
Moribund Sacrifice 2
Natural Death 1
Survivors
Terminal Sacrifice 5 5 5 5 5 2
Animals Examined Microscopically 5 5 5 5 5 5
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (5) (5) (5) (5) (5) (5)
Inflammation, Focal 5 (100%) 5 (100%) 4 (80%) 1 (20%) 1 (20%) 1 (20%)
Necrosis, Focal 2 (40%)
Hepatocyte, Vacuolization Cytoplasmic 1 (20%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (5) (5) (5) (5) (5) (5)
Atrium, Thrombosis 1 (20%) 2 (40%)
Myocardium, Ventricle, Mineralization 1 (20%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
None
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
None
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 96002-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 14DAY REPEATED DIAZOAMINOBENZENE (DAAB) Date: 09/27/00
Route: SKIN APPLICATION Time: 08:19:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 12.5 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Bone Marrow (5) (5) (5)
Myeloid Cell, Hyperplasia 1 (20%)
Lymph Node, Mandibular (4) (5) (5) (5) (4) (4)
Atrophy 3 (75%)
Lymph Node, Mesenteric (5) (5) (5) (5) (3) (4)
Atrophy 1 (33%) 1 (25%)
Spleen (5) (5) (5) (5) (5) (5)
Hematopoietic Cell Proliferation 5 (100%) 5 (100%) 5 (100%) 2 (40%) 2 (40%)
Lymphoid Follicle, Atrophy 3 (60%) 2 (40%)
Thymus (5) (5) (5) (5) (5) (4)
Atrophy 4 (80%) 5 (100%) 3 (75%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (5) (5) (5) (5) (5) (5)
Epidermis, Skin, Site of Application,
Hyperplasia 5 (100%) 5 (100%) 5 (100%) 5 (100%) 5 (100%)
Hair Follicle, Skin, Site of Application,
Hyperplasia 5 (100%) 5 (100%) 5 (100%) 5 (100%) 5 (100%)
Skin, Site of Application, Inflammation 5 (100%) 5 (100%) 5 (100%) 5 (100%) 5 (100%)
Skin, Site of Application, Ulcer 1 (20%) 2 (40%) 4 (80%) 2 (40%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (5) (5) (5)
Artery, Inflammation 1 (20%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 96002-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 14DAY REPEATED DIAZOAMINOBENZENE (DAAB) Date: 09/27/00
Route: SKIN APPLICATION Time: 08:19:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 12.5 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (5) (5) (5) (5) (5) (5)
Bilateral, Cortex, Renal Tubule, Dilatation 4 (80%)
Bilateral, Cortex, Renal Tubule, Necrosis 4 (80%) 1 (20%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 96002-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 14DAY REPEATED DIAZOAMINOBENZENE (DAAB) Date: 09/27/00
Route: SKIN APPLICATION Time: 08:19:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 12.5 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 5 5 5 5 5 5
Early Deaths
Moribund Sacrifice 4 5 5
Survivors
Terminal Sacrifice 5 5 5 1
Animals Examined Microscopically 5 5 5 5 5 5
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (5) (5) (5) (5) (5) (5)
Inflammation, Focal 4 (80%) 1 (20%) 1 (20%) 1 (20%)
Mineralization 1 (20%)
Necrosis, Focal 3 (60%) 5 (100%)
Hepatocyte, Vacuolization Cytoplasmic 1 (20%) 1 (20%)
Stomach, Forestomach (5) (5) (5) (5) (5) (5)
Ulcer, Focal 2 (40%) 2 (40%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (5) (5) (5) (5) (5) (5)
Atrium, Thrombosis 2 (40%) 5 (100%) 5 (100%)
Myocardium, Atrium, Mineralization 1 (20%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
None
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Penis (2) (1) (1)
Congestion 1 (50%)
Testes (5) (5) (5) (5) (5) (5)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 96002-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 14DAY REPEATED DIAZOAMINOBENZENE (DAAB) Date: 09/27/00
Route: SKIN APPLICATION Time: 08:19:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 12.5 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Germinal Epithelium, Degeneration 2 (40%) 1 (20%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (5) (5) (5) (5) (5)
Myeloid Cell, Hyperplasia 1 (20%)
Lymph Node, Mandibular (5) (5) (5) (5) (4) (5)
Atrophy 3 (60%) 4 (100%) 5 (100%)
Lymph Node, Mesenteric (4) (5) (4) (5) (5) (4)
Atrophy 2 (40%) 3 (60%) 4 (100%)
Spleen (5) (5) (5) (5) (5) (5)
Hematopoietic Cell Proliferation 5 (100%) 5 (100%) 2 (40%) 1 (20%)
Lymphoid Follicle, Atrophy 1 (20%) 2 (40%) 5 (100%)
Thymus (5) (5) (5) (5) (5) (5)
Atrophy 5 (100%) 5 (100%) 5 (100%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (5) (5) (5) (5) (5) (5)
Epidermis, Skin, Site of Application,
Hyperplasia 5 (100%) 5 (100%) 5 (100%) 5 (100%) 5 (100%)
Epidermis, Skin, Site of Application,
Inflammation, Focal 1 (20%)
Hair Follicle, Skin, Site of Application,
Hyperplasia 5 (100%) 5 (100%) 5 (100%) 5 (100%) 2 (40%)
Skin, Site of Application, Inflammation 5 (100%) 5 (100%) 5 (100%) 5 (100%) 5 (100%)
Skin, Site of Application, Ulcer 1 (20%) 1 (20%) 1 (20%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 96002-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 14DAY REPEATED DIAZOAMINOBENZENE (DAAB) Date: 09/27/00
Route: SKIN APPLICATION Time: 08:19:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 12.5 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Lung (5) (5) (5) (5) (5)
Artery, Mineralization 1 (20%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (5) (5) (5) (5) (5) (5)
Bilateral, Cortex, Renal Tubule, Necrosis 5 (100%) 5 (100%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------